Date(s) - June 21,2019 - June 23,2019
8:00 am - 1:00 pm
Marriott Marquis San Diego
Dr. Gregory Holmquist, Pharm D., CPE
Certified Pain Educator
Dr. Gregory Holmquist is a pain and palliative care specialist. He is on the Board of Advisors of the American Society of Pain Educators. Over the past two decades, Greg has been invited to present over 2000 CME and CE lectures on pain management across the country. He shares practical and relevant clinical information, with a touch of humor, ensuring that audiences not only listen but also hear an important message on managing pain and making a difference in the lives of their patients.
Friday, June 21, 2019
1. Discuss the burden of opioid misuse and abuse on the individual and society.
2. Describe how the use of opioids in acute, chronic, and cancer pain has changed in the past 20 years.
3. Compare and contrast the current best practice model for the use of opioids in acute postoperative pain, chronic low back pain, neuropathic pain, fibromyalgia, and end-of-life pain.
4. Describe current laws and regulations regarding opioid prescribing for acute, chronic, and end-of-life pain.
5. Differentiate addiction, physical dependency, tolerance and hyperalgesia and be able to counsel patients and providers on the potential impact these may have on the morbidity associated with opioid use.
6. Identify typical characteristics of patients who would be identified as “high risk”, “moderate risk” and “low risk” for chronic opioid misuse and describe the best practice model for pharmacists to assist providers in properly monitoring these patients when they are receiving opioid therapy.
7. Describe how a pharmacist should counsel patients who are started on opioids to minimize the risks of adverse reactions, over-dosage and inappropriate compliance.
8. Describe how non-opioid medications can be utilized to lower the overall use of opioids while continuing to achieve effective pain control.
9. State how to prevent/minimize hyperalgesia-induced opioid dose escalation.
10. State common side effects associated with opioids and be able to recommend strategies to prevent the side effects from impacting the patient’s quality of life.
11. Give examples of opioid products that have “abuse-deterrent” technology and be able to recommend to prescribers how these products could be utilized to improve patient and community safety.
Dr. Joshua Neumiller, Pharm D, CDE, FASCP
Washington State University
Dr. Josh Neumiller is Vice-Chair and Associate Professor in the Department of Pharmacotherapy at Washington State University. Dr Neumiller is a Certified Diabetes Educator (CDE) and a fellow of the American Society of Consultant Pharmacists. Josh is a contributing author for the ADA books Medications for the Treatment of Diabetes, Practical Insulin, and the American Diabetes Association Guide to Nutrition Therapy for Diabetes, and is the Editor-in Chief for the ADA journal Diabetes Spectrum. Josh’s research interests involve the management of diabetes and prevention of adverse drug events during transitions in care. Josh has practiced extensively in the geriatric community. Josh was recently awarded the 2016 Albert B. Prescott Pharmacy Leadership Award.
Saturday June 22, 2019